<SEC-DOCUMENT>0001104659-22-000998.txt : 20220104
<SEC-HEADER>0001104659-22-000998.hdr.sgml : 20220104
<ACCEPTANCE-DATETIME>20220104172129
ACCESSION NUMBER:		0001104659-22-000998
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220103
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220104
DATE AS OF CHANGE:		20220104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		22507532

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm221380d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:syn="http://syntheticbiologics.com/20220103">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_syn_syntheticbiologics.com_20220103 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20220103_20220103 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000894158 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:EntityCentralIndexKey">0000894158</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-03to2022-01-03" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="syn-20220103.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-03to2022-01-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-03</xbrli:startDate>
        <xbrli:endDate>2022-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20220103__20220103_zQU1gwCcr8ei"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_908_edei--DocumentPeriodEndDate_c20220103__20220103_z8DXem9povSc"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">January 3, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityRegistrantName_c20220103__20220103_zo21HdlXxjN5"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:EntityRegistrantName">SYNTHETIC BIOLOGICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20220103__20220103_z16ozyoHyxgc"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20220103__20220103_zoKTUKMxki48"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:EntityFileNumber">001-12584</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20220103__20220103_zkLkr9GPwRa5"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:EntityTaxIdentificationNumber">13-3808303</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</p></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">(Commission File No.)</span></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20220103__20220103_zjtIcggQJ2T1"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:EntityAddressAddressLine1">9605 Medical Center Drive</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20220103__20220103_zw1AInjtTqbg"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:EntityAddressAddressLine2">Suite 270</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20220103__20220103_zE0QnV7jfLS9"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20220103__20220103_zm5eSVstetBb"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20220103__20220103_zMFVg2AIPdc6"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90B_edei--CityAreaCode_c20220103__20220103_zpysURVZWEJi"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:CityAreaCode">301</ix:nonNumeric></span>) <span id="xdx_902_edei--LocalPhoneNumber_c20220103__20220103_zmeWyDqIQwKd"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:LocalPhoneNumber">417-4364</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90A_edei--WrittenCommunications_c20220103__20220103_zaDxyH2lar23"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90B_edei--SolicitingMaterial_c20220103__20220103_zTFVZkRn35Yk"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_900_edei--PreCommencementTenderOffer_c20220103__20220103_zNcNIAaxgl7h"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20220103__20220103_zH1phQ466xYi"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20220103__20220103_zi7P6Tk3raj6"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20220103__20220103_zKcArmuJFQr1"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" name="dei:TradingSymbol">SYN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_edei--SecurityExchangeName_c20220103__20220103_zopdTPrbP73l"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20220103__20220103_zLtObtfipIQd"><ix:nonNumeric contextRef="From2022-01-03to2022-01-03" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 3, 2022, Synthetic Biologics, Inc.
(the &#8220;Company&#8221;) entered into a three-year employment agreement with Steven A. Shallcross (the &#8220;Employment Agreement&#8221;),
who has served as the Company&#8217;s Chief Executive Officer since December 6, 2018 and as the Company&#8217;s Chief Financial Officer
since June 1, 2015 to continue to serve as the Chief Executive Officer and Chief Financial Officer of the Company. The Employment Agreement
replaced the prior employment agreement with the Company that Mr. Shallcross entered into on December 6, 2018, as amended December 5,
2019. The material terms of the Employment Agreement are set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Employment Agreement, Mr. Shallcross
is entitled to an annual base salary of $585,000 and an annual cash performance bonus of up to fifty percent (50%) of his annual base
salary as well as discretionary annual equity awards pursuant to the Company&#8217;s incentive plans. The annual bonus will be based upon
the assessment of the Board of Mr. Shallcross&#8217;s performance. The Employment Agreement also includes confidentiality obligations
and inventions assignments by Mr. Shallcross and non-solicitation and non-competition provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Employment Agreement has a stated term of
three years but may be terminated earlier pursuant to its terms. If Mr. Shallcross&#8217;s employment is terminated for any reason, he
or his estate as the case may be, will be entitled to receive the unpaid base salary through the date of termination and accrued vacation,
any unpaid annual bonus earned with respect to any calendar year ending on or preceding the date of termination, expense reimbursement
and any other entitlements accrued by him to the extent not previously paid (the &#8220;Accrued Obligations&#8221;); provided, however,
that if his employment is terminated (i) by the Company without Cause or by Mr. Shallcross for Good Reason (as each is defined in the
Employment Agreement) then, subject to him executing a general release in form acceptable to the Company that becomes effective, in addition
to paying the Accrued Obligations, (a) the Company will continue to pay his then current base salary and if the Executive timely elects
continued coverage under COBRA, the Company will continue to provide benefits at least equal to those that were provided at the time of
termination for a period of twelve (12) months and (b) all unvested equity awards will vest and he shall have the right to exercise any
such vested equity awards until the earlier of eighteen (18) months after termination or the remaining term of the awards; or (ii) by
reason of his death or Disability (as defined in the Employment Agreement), then in addition to paying the Accrued Obligations, Mr. Shallcross
or his estate would have the right to exercise any vested options until the earlier of six (6) months after termination or the remaining
term of the awards. In such event, if Mr. Shallcross commenced employment with another employer and becomes eligible to receive medical
or other welfare benefits under another employer-provided plan, the medical and other welfare benefits to be provided by the Company as
described herein would terminate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Employment Agreement provides that upon the
closing of a &#8220;Change in Control&#8221; (as defined in the Employment Agreement), all unvested options shall immediately vest and
the time period that Mr. Shallcross will have to exercise all vested stock options and other awards that Mr. Shallcross may have will
be equal to the shorter of: (i) eighteen (18) months after termination, or (ii) the remaining term of the award(s). If within one (1)
year after the occurrence of a Change in Control, Mr. Shallcross terminates his employment for &#8220;Good Reason&#8221; or the Company
terminates Mr. Shallcross&#8217;s employment for any reason other than death, disability or Cause, Mr. Shallcross will be entitled to
receive: (i) the portion of his base salary for periods prior to the effective date of termination accrued but unpaid (if any); (ii) all
unreimbursed expenses (if any); (iii) an aggregate amount (the &#8220;Change in Control Severance Amount&#8221;) equal to two (2) times
the sum of his base salary plus an amount equal to the bonus that would be payable if the &#8220;target&#8221; level performance were
achieved under the Company&#8217;s annual bonus plan (if any) in respect of the fiscal year during which the termination occurs (or the
prior fiscal year if bonus levels have not yet been established for the year of termination) subject to him executing a general release
in form acceptable to the Company that becomes effective. If within two (2) years after the occurrence of a Change in Control, Mr. Shallcross
terminates his employment for &#8220;Good Reason&#8221; or the Company terminates Mr. Shallcross&#8217;s employment for any reason other
than death, disability or Cause, Mr. Shallcross will be entitled to also receive for the period of two (2) consecutive years commencing
on the date of such termination of his employment, medical, dental, life and disability insurance coverage for him and the members of
his family that are not less favorable to him than the group medical, dental, life and disability insurance coverage carried by the Company
for him subject to him executing a general release in form acceptable to the Company that becomes effective. The Change in Control Severance
Amount is to be paid in a lump sum if the Change in Control event constitutes a &#8220;change in the ownership&#8221; or a &#8220;change
in the effective control&#8221; of the Company or a &#8220;change in the ownership of a substantial portion of a corporation&#8217;s assets&#8221;
(each within the meaning of Section 409A of the Internal Revenue Code (&#8220;Rule 409A&#8221;)), or in 48 substantially equal payments,
if the Change in Control event does not so comply with Section 409A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in this Item 5.02 regarding
the Employment Agreement is qualified in its entirety by a copy of the Employment Agreement attached to this Current Report on Form 8-K
as Exhibit 10.1 and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(d)&#160;&#160;</span></td>
    <td style="width: 96%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit<br />
Number</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 89%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><a href="tm221380d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm221380d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Employment Agreement with Steven Shallcross dated January 3, 2022</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Cover Page Interactive Data File (embedded within the XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Dated: January 4, 2022</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif">SYNTHETIC BIOLOGICS, INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 42%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0">Chief Executive Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0">and Chief Financial Officer</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LW4d6GSXDhVxyhgi3hYXpbg1I60/eyTf0m5DDIGQnPPlCDERG1rrGhnOyzKHIzZtrRxCiVdkNBf0jmy7S8HPEm/aOlbGDesPzMgz6JnZdKH8fXA+tcUqhWgeyiSMJURJKhMo9iLo9YzMVVdonFY1KFNBwdSyRqe4Gz8c1ZsMNd2QdEK2mkwKchqN8gfiSMZwoKd6Ed8t5HkmgslQgdgwPdo+5mEdNbCqsfFZdkT/HXwB5GpJJA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm221380d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EMPLOYMENT
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
EMPLOYMENT AGREEMENT (the &#8220;<B><I>Agreement</I></B>&#8221;) between Synthetic Biologics, Inc., a Nevada corporation, (the &#8220;<B><I>Company</I></B>&#8221;),
and Steven A. Shallcross (the &#8220;<B><I>Executive</I></B>&#8221;) is effective as of January 3, 2022 (the &#8220;<B><I>Effective Date</I></B>&#8221;)
and replaces and supersedes the employment agreement between the Executive and the Company dated December 6, 2018 as amended December
5, 2019 (the &#8220;<B><I>Prior Agreement</I></B>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">W
I T N E S S E T H:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B>,
the Executive has been employed by the Company as its Chief Executive Officer and Chief Financial Officer pursuant to the terms of the
Prior Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B>,
the Company desires to continue to employ the Executive as its President and Chief Executive Officer and as its Chief Financial Officer
and the Executive desires to accept such employment, on the terms and conditions set forth in this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B>,
the Company and the Executive have mutually agreed that, as of the Effective Date, this Agreement shall replace the Prior Employment
Agreement in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE</B>, in consideration of the promises and the mutual covenants and agreements contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby,
agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>EMPLOYMENT</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TERMINATION OF PRIOR EMPLOYMENT AGREEMENT</U>. Effective as of 11:59 p.m. on the day immediately prior to the Effective Date,
the Prior Employment Agreement shall automatically terminate and be of no further force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>EMPLOYMENT TERM</U>. The Company hereby offers to continue to employ the Executive, and the Executive hereby accepts continued
employment by the Company, upon the terms and conditions set forth in this Agreement, until the termination of the Executive&#8217;s
employment in accordance with Section 10 below, as applicable (the &#8220;<B><I>Employment Term</I></B>&#8221;). The Executive shall
be employed for three years unless there is an earlier termination in accordance with Section 10 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>POSITION &amp; DUTIES</U></B>. During the Employment Term, the Executive shall serve as the Company&#8217;s President, Chief
Executive Officer and Chief Financial Officer. As President, Chief Executive Officer and Chief Financial Officer, the Executive shall
have such duties, authorities and responsibilities commensurate with the duties, authorities and responsibilities of persons in similar
capacities in similarly sized companies and such other duties and responsibilities as the Company&#8217;s Board of Directors (the &#8220;<B><I>Board</I></B>&#8221;)
shall designate that are consistent with the Executive&#8217;s position as President, Chief Executive Officer and Chief Financial Officer,
including directing, supervising and having responsibility for all aspects of the operations and general affairs of the Company as directed
by the Board. The Executive shall report to, and be subject to, the lawful direction of the Board. During the Employment Term, the Executive
shall use his best efforts to perform faithfully and efficiently the duties and responsibilities assigned to the Executive hereunder
and devote all of the Executive&#8217;s business time (excluding periods of vacation and other approved leaves of absence) to the performance
of the Executive&#8217;s duties with the Company. During the Term, the Executive shall also serve, without additional compensation, as
a member of the Board and the board of directors of the Company&#8217;s subsidiaries and in such other executive-level positions or capacities
as may, from time to time, be reasonably requested by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>LOCATION</U></B>. Unless the parties otherwise agree in writing, at all times during the Employment Term, the Executive&#8217;s
principal place of business for performance of the services under this Agreement shall be in Rockville, Maryland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>BASE SALARY</U></B>. The Company agrees to pay the Executive a base salary (the &#8220;<B><I>Base Salary</I></B>&#8221;)
at an annual rate of $585,000, payable semi-monthly in accordance with the regular payroll practices of the Company. The Executive&#8217;s
Base Salary shall be subject to review and adjustment from time to time by the Board (or a committee thereof) in its sole discretion,
but may not be decreased. The base salary as determined herein from time to time shall constitute &#8220;Base Salary&#8221; for purposes
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>ANNUAL BONUS</U></B>. With respect to each calendar year during the Employment Term (beginning in the year of the Effective
Date), the Executive will be eligible to earn a cash annual performance bonus (the &#8220;<B><I>Annual Bonus</I></B>&#8221;). Beginning
in the 2022 calendar year and for each full calendar year thereafter, the Executive will be eligible for an Annual Bonus of up to fifty
percent (50%) of the Base Salary. The Annual Bonus will be based upon the Board&#8217;s assessment of the Executive&#8217;s performance
and the Company&#8217;s attainment of targeted goals as set by the Board in its sole discretion. The Annual Bonus, if any, will be subject
to applicable payroll deductions and withholdings. Following the close of each calendar year, the Board will determine whether the Executive
has earned the Annual Bonus, and the amount of any Annual Bonus, based on the set criteria. No amount of the Annual Bonus is guaranteed,
and the Executive must be an employee in good standing through the end of the applicable calendar year to be eligible to receive an Annual
Bonus; no partial or prorated bonuses will be provided. The Annual Bonus, if earned, will be paid on or about December 1, but no later
than December 31, of the applicable calendar year for which the Annual Bonus is being measured. The Executive&#8217;s eligibility for
an Annual Bonus is subject to change in the discretion of the Board (or any authorized committee thereof). In addition, the Executive
will also be eligible to receive annual equity awards pursuant to the Company&#8217;s incentive equity plans, such awards (including
the number and type of awards), if any, to be in the sole discretion of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>EQUITY</U></B>. In accordance with the terms of the various Option Grant Agreements entered into between the Executive and
the Company (collectively, the &#8220;<B><I>Grant Agreements</I></B>&#8221;), the Executive has been granted options to purchase an aggregate
of One Million Eight Hundred Eight Thousand Five Hundred Seventy Five (1,808,575) shares of the Company&#8217;s publicly traded common
stock (the &#8220;<B><I>Grant</I></B>&#8221;) subject to the terms of the Company&#8217;s 2020 Stock Incentive Plan, 2001 Stock Incentive
Plan, 2007 Stock Incentive Plan, 2010 Stock Incentive Plan and 2020 Stock Incentive Plan (the &#8220;<B><I>Plans</I></B>&#8221;) and
the related Grant Agreements between the parties. Except as specifically provided herein, the provisions of the Grant Agreements and
the Executive&#8217;s rights with respect to the grants thereunder shall continue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <B><U>EMPLOYEE BENEFITS</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>BENEFIT PLANS</U>. The Executive shall, in accordance with Company policy and the terms of the applicable Company benefit plan
documents, be eligible to participate in any benefit plan or arrangement, including health, life and disability insurance, retirement
plans and the like, that may be in effect from time to time and made available to the Company&#8217;s senior management. All matters
of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions of such plan. The
Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion. Notwithstanding the foregoing, in
the event that the terms of this Agreement differ from or are in conflict with the Company&#8217;s general employment policies or practices,
this Agreement shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>VACATION</U>. The Executive shall be entitled to twenty-two (22) days paid vacation and sick leave per year in accordance with
the Company&#8217;s policies and shall be entitled to accrue ten (10) days of vacation time during the Employment Term in accordance
with the Company&#8217;s vacation policy. Vacation is to be taken at such intervals as shall be appropriate and consistent with the proper
performance of the Executive&#8217;s duties hereunder. The existing vacation accrued for the past four (4) years to date not to exceed
sixty (60) days will rollover into this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>SUPPLEMENTAL DISABILITY BENEFITS</U>. During the Employment Term, the Company will pay for the applicable premiums for the
Executive&#8217;s coverage under its existing supplemental disability policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>GENERAL EXPENSE REIMBURSEMENTS</U>. The Company will reimburse the Executive for all reasonable business expenses, including
travel, computer and cellular phone costs that the Executive incurs in performing the services hereunder pursuant to the Company&#8217;s
usual expense reimbursement policies and practices, following submission by the Executive of reasonable documentation thereof. All reimbursements
provided under this Agreement shall be made in accordance with the requirements of Section 409A (as defined below) to the extent that
such reimbursements are subject to Section 409A, including, as applicable, the requirements that (i) any reimbursement is for expenses
incurred during the Employment Term, (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the
expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense shall be made on or before
the last day of the calendar year following the calendar year in which the expense was incurred, and (iv) the right to reimbursement
is not subject to liquidation or exchange for any other benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>INDEMNIFICATION</U>. The Company shall provide the Executive with full advance indemnification to the extent permitted by Nevada
law, including indemnification for activities at all subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>CONFIDENTIALITY AND POST-EMPLOYMENT OBLIGATIONS</U></B>. Executive agrees that the Company&#8217;s form of Proprietary Information,
Inventions, Non-Solicitation and Non-Competition Agreement dated February 27, 2017 (the &#8220;<B><I>Confidentiality Agreement</I></B>&#8221;),
which Executive had executed remains in full force and effect. The Confidentiality Agreement may be amended by the parties from time
to time without regard to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Confidentiality Agreement contains provisions that are intended by the parties to survive and do survive termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>OUTSIDE ACTIVITIES DURING EMPLOYMENT</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>NO ADVERSE INTERESTS</U>. The Executive agrees not to acquire, assume or participate in, directly or indirectly, any position,
investment or interest known by him to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise during
the Employment Term without the consent of the Board. Except with the prior written consent of the Board, during the Employment Term
the Executive will not undertake or engage in any other employment, occupation or business enterprise. Notwithstanding the foregoing,
nothing shall not prevent the Executive from participating in charitable, civic, educational, professional, community or industry affairs
or, with prior approval of the Board, serving on the board of directors or advisory boards of other companies; <I>provided that</I> such
activities or services do not (i) create a conflict with his employment hereunder; (ii) materially interfere with the performance of
his duties; or (iii) violate the terms of the Confidentiality Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>NONCOMPETITION</U>. Other than as permitted by Section 9(a), during the Employment Term and for the one year period thereafter
(the &#8220;<B><I>Non-Competition Period</I></B>&#8221;), except on behalf of the Company, the Executive will not directly or indirectly,
whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever
engage in, become financially interested in, participate in, be employed by or have any business connection with any other person, corporation,
firm, partnership or other entity whatsoever which competes with the Company, anywhere throughout the world, in any line of business
engaged in (or planned to be engaged in) by the Company other than <I>de minimis</I> stock holdings in public companies; <I>provided,
however,</I> that anything above to the contrary notwithstanding, he may own, as a passive investor, securities of any competitor corporation,
so long as his direct holdings in any one such corporation shall not in the aggregate constitute more than one percent (1%) of the voting
stock of such corporation, and <I>provided that</I> the Executive promptly discloses to the Board any such participation, other than
such <I>de minimis</I> stock holdings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>NONSOLICITATION</U><FONT STYLE="font-size: 10pt">. </FONT>During the Non-Competition Period, Executive shall not, directly
or indirectly, (i) induce or attempt to induce or aid others in inducing anyone working at or for the Company to cease working at or
for the Company, or in any way interfere with the relationship between the Company and anyone working at or for the Company except in
the proper exercise of Executive&#8217;s authority or (ii) in any way interfere with the relationship between the Company and any customer,
supplier, licensee or other business relation of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>SCOPE</U>.&nbsp;&nbsp;If, at the time of enforcement of this Section 9, a court shall hold that the duration, scope, area or
other restrictions stated herein are unreasonable under circumstances then existing, the parties agree that the maximum duration, scope,
area or other restrictions reasonable under such circumstances shall be substituted for the stated duration, scope, area or other restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>INDEPENDENT AGREEMENT</U>.&nbsp;&nbsp;The covenants made in this Section 9 shall be construed as an agreement independent of any other
provisions of this Agreement, and shall survive the termination of this Agreement.&nbsp;&nbsp;Moreover, the existence of any claim or
cause of action of Executive against the Company or any of its affiliates, whether or not predicated upon the terms of this Agreement,
shall not constitute a defense to the enforcement of these covenants.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>TERMINATION</U></B>. The Executive&#8217;s employment and the Employment Term shall terminate on the first of the following
to occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>DISABILITY</U>. Upon the 30<SUP>th</SUP> day following the Executive&#8217;s receipt of notice of the Company&#8217;s termination
due to Disability (as defined in this Section); <I>provided that</I>, the Executive has not returned to full-time performance of his
duties within thirty (30)&nbsp;days after receipt of such notice. If the Company determines in good faith that the Executive&#8217;s
Disability has occurred during the term of this Agreement, it will give the Executive written notice of its intention to terminate his
employment.&nbsp; For purposes of this Agreement, &#8220;<B><I>Disability</I></B>&#8221; shall occur when the Board determines that the
Executive has become physically or mentally incapable of performing the essential functions of his job duties under this Agreement with
or without reasonable accommodation, for ninety (90) consecutive days or one hundred twenty (120) nonconsecutive days in any twelve (12)
month period, subject to any applicable law. For purposes of this Section, at the Company&#8217;s request, the Executive agrees to make
himself available and to cooperate in a reasonable examination by an independent qualified physician selected by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>DEATH</U>. Automatically on the date of death of the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>CAUSE</U>. Immediately upon written notice by the Company to the Executive of a termination for Cause. For purposes of this
Agreement, &#8220;<B><I>Cause</I></B>&#8221; shall mean the occurrence of any of the following events, as determined by the Board in
its sole and absolute discretion: (i) gross insubordination, acts of embezzlement or misappropriation of funds, fraud, dereliction of
fiduciary obligations; (ii) conviction of a felony or other crime involving moral turpitude, dishonesty or theft (including entry of
a <I>nolo contendere</I> plea); (iii) willful unauthorized disclosure of confidential information belonging to the Company or entrusted
to the Company by a client; (iv) material violation of any provision of this Agreement, of any Company policy, and/or of the Confidentiality
Agreement, which, to the extent it is curable by the Executive, is not cured by the Executive within thirty (30) days of receiving written
notice of such violation by the Company; (v) being under the influence of drugs (other than prescription medicine or other medically-related
drugs to the extent that they are taken in accordance with their directions) during the performance of the Executive&#8217;s duties under
this Agreement; (vi) engages in conduct that violates the Company&#8217;s non-discrimination/harassment policy and warrants termination;
(vii) willful failure to perform his written assigned tasks, where such failure is attributable to the fault of the Executive which,
to the extent it is curable by the Executive, is not cured by Executive within thirty (30) days of receiving written notice of such violation
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>WITHOUT CAUSE</U>. Upon written notice by the Company to the Executive of an involuntary termination without Cause and other
than due to death or Disability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>WITH GOOD REASON</U>. Upon the Executive&#8217;s notice following the end of the Cure Period (as defined in this Section).
For purposes of this Agreement, &#8220;<B><I>Good Reason</I></B>&#8221; for the Executive to terminate his employment hereunder shall
mean the occurrence of any of the following events without the Executive&#8217;s consent: (i) a material reduction in the Executive&#8217;s
Base Salary (other than an across-the-board decrease in base salary applicable to all executive officers of the Company); (ii) a material
breach of this Agreement by the Company; (iii) a material reduction in the Executive&#8217;s duties, authority and responsibilities relative
to the Executive&#8217;s duties, authority, and responsibilities in effect immediately prior to such reduction; or (iv) the relocation
of the Executive&#8217;s principal place of employment, without the Executive&#8217;s consent, in a manner that lengthens his one-way
commute distance by fifty (50) or more miles from his then-current principal place of employment immediately prior to such relocation;
<I>provided, however, </I>that, any such termination by the Executive shall only be deemed for Good Reason pursuant to this definition
if: (1) the Executive gives the Company written notice of his intent to terminate for Good Reason within thirty (30) days following the
first occurrence of the condition(s) that he believes constitute(s) Good Reason, which notice shall describe such condition(s); (2) the
Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the &#8220;<B><I>Cure Period</I></B>&#8221;);
and (3) the Executive voluntarily terminates his employment within thirty (30) days following the end of the Cure Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>WITHOUT GOOD REASON</U>. Upon the expiration of the Transition Period (as defined in this Section) unless otherwise provided
by the Company as provided herein, the Executive shall provide thirty (30) days&#8217; prior written notice (the &#8220;<B><I>Transition
Period</I></B>&#8221;) to the Company of the Executive&#8217;s intended termination of employment without Good Reason (&#8220;<B><I>Voluntary
Termination</I></B>&#8221;). During the Transition Period, the Executive shall assist and advise the Company in any transition of business,
customers, prospects, projects and strategic planning, and the Company shall continue to pay Executive&#8217;s Base Salary and benefits
through the end of the Transition Period. The Company may, in its sole discretion, upon five (5) days prior written notice to the Executive,
make such termination of employment effective earlier than the expiration of the Transition Period (&#8220;<B><I>Early Termination Right</I></B>&#8221;),
but it shall pay the Executive&#8217;s Base Salary and benefits through the earlier of: the end of the Transition Period, or the date
that the Executive accepts full-time employment or a full-time consulting engagement from a third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>CONSEQUENCES OF TERMINATION</U></B>. Any termination payments made and benefits provided under this Agreement to the Executive
shall be in lieu of any termination or severance payments or benefits for which the Executive may be eligible under any of the plans,
policies or programs of the Company or its affiliates as may be in effect from time to time. Subject to satisfaction of each of the conditions
set forth in Section 12, the following amounts and benefits shall be due to the Executive. Any Accrued Amounts (as defined in Section
11(a)) shall be payable on the next regularly scheduled Company payroll date following the date of termination or earlier if required
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>DISABILITY</U>. Upon employment termination due to Disability, the Company shall pay or provide the Executive: (i) any unpaid
Base Salary through the date of termination and any accrued vacation; (ii) any unpaid Annual Bonus earned with respect to any calendar
year ending on or preceding the date of termination; (iii) reimbursement for any unreimbursed expenses incurred through the date of termination;
and (iv) all other payments and benefits to which the Executive may be entitled under the terms of any applicable compensation arrangement
or benefit, equity or perquisite plan or program or grant or this Agreement, including but not limited to any applicable insurance benefits
(collectively, &#8220;<B><I>Accrued Amounts</I></B>&#8221;). In addition, upon the Executive&#8217;s termination due to Disability, the
Executive shall be entitled to exercise any vested equity award(s) granted to the Executive for a period equal to the shorter of: (i)
six (6) months after termination, or (ii) the remaining term of the award(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>DEATH</U>. In the event the Employment Term ends on account of the Executive&#8217;s death, the Executive&#8217;s estate (or
to the extent a beneficiary has been designated in accordance with a program, the beneficiary under such program) shall be entitled to
any Accrued Amounts, including but not limited to proceeds from any Company sponsored life insurance programs. In addition, upon the
Executive&#8217;s death, the Company will extend the time period that the Executive&#8217;s estate (or to the extent a beneficiary has
been designated in accordance with a program, the beneficiary under such program) shall be entitled to exercise any vested equity award(s)
granted to the Executive for a period equal to the shorter of: (i) six (6) months after termination, or (ii) the remaining term of the
award(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TERMINATION FOR CAUSE OR WITHOUT GOOD REASON</U>. If the Executive&#8217;s employment should be terminated (i) by the Company
for Cause, or (ii) by the Executive without Good Reason, the Company shall pay to the Executive any Accrued Amounts only, and shall not
be obligated to make any additional payments to the Executive. In addition, upon the Executive&#8217;s termination by the Company for
Cause, or by the Executive for Good Reason, all options not exercised shall terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TERMINATION WITHOUT CAUSE OR FOR GOOD REASON</U>. If the Executive&#8217;s employment by the Company is terminated by the Company
without Cause (and not due to Disability or death) or by the Executive for Good Reason, then the Company shall pay or provide the Executive
with the Accrued Amounts and subject to compliance with Section 12:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">i.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>continued payment of the Executive&#8217;s Base Salary as in effect immediately preceding the last day of the Employment Term
(ignoring any decrease in Base Salary that forms the basis for Good Reason), for a period of twelve (12) months following the termination
date (the &#8220;<B><I>Severance Period</I></B>&#8221;) on the Company&#8217;s regular payroll dates; <I>provided, however,</I> that
any payments otherwise scheduled to be made prior to the effective date of the General Release (namely, the date it can no longer be
revoked) shall accrue and be paid in the first payroll date that follows such effective date with subsequent payments occurring on each
subsequent Company payroll date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ii.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if the Executive timely elects continued coverage under COBRA for himself and his covered dependents under the Company&#8217;s
group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue the Executive&#8217;s
and his covered dependents&#8217; health insurance coverage in effect for himself (and his covered dependents) on the termination date
until the earliest of (i) twelve (12) months following the termination date; (ii) the date when the Executive becomes eligible for substantially
equivalent health insurance coverage in connection with new employment or self-employment; or (iii) the date the Executive ceases to
be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the termination date through
the earlier of (i)-(iii), the &#8220;<B><I>COBRA Payment Period</I></B>&#8221;). Notwithstanding the foregoing, if at any time the Company
determines that its payment of COBRA premiums on the Executive&#8217;s behalf would result in a violation of applicable law (including
but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation
Act), then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay the Executive on the last day of each remaining
month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax
withholding (such amount, the &#8220;<B><I>Special Severance Payment</I></B>&#8221;), such Special Severance Payment to be made without
regard to the Executive&#8217;s payment of COBRA premiums and without regard to the expiration of the COBRA period prior to the end of
the COBRA Payment Period. Nothing in this Agreement shall deprive the Executive of his rights under COBRA or ERISA for benefits under
plans and policies arising under his employment by the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">iii.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all unvested stock options and other equity awards shall immediately vest and Executive shall be entitled to exercise any vested
equity awards for a period equal to the shorter of: (i) eighteen (18) months after termination, or (ii) the remaining term of the award(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the Executive&#8217;s employment by the Company is terminated by the Company without Cause (and not due to Disability or death) or by
the Executive for Good Reason, then the Executive will be eligible to receive additional severance benefits including, but not limited
to, a pro-rata portion of the Executive&#8217;s Annual Bonus, as determined by the Board of Directors, for the performance year in which
the Executive&#8217;s termination occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>CONDITIONS</U></B>. Any payments or benefits made or provided pursuant to Section&nbsp;11 (other than Accrued Amounts) are
subject to the Executive&#8217;s (or, in the event of the Executive&#8217;s death, the beneficiary&#8217;s or estate&#8217;s, or in the
event of the Executive&#8217;s Disability, the guardian&#8217;s):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>compliance with the provisions of Section 8 hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>delivery to the Company of an executed waiver and general release of any and all known and unknown claims, and other provisions
and covenants, in the form acceptable to the Company (which shall be delivered to the Executive within five (5) business days following
the termination date) (the &#8220;<B><I>General Release</I></B>&#8221;) within 21 days of presentation thereof by the Company to the
Executive (or a longer period of time if required by law), and permitting the General Release to become effective in accordance with
its terms; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>delivery to the Company of a resignation from all offices, directorships and fiduciary positions with the Company, its affiliates
and employee benefit plans effective as of the termination date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the due date of any post-employment payments, any amounts due following a termination under this Agreement (other than Accrued Amounts)
shall not be due until after the expiration of any revocation period applicable to the General Release without the Executive having revoked
such General Release, and any such amounts shall be paid or commence being paid to the Executive within fifteen (15) days of the expiration
of such revocation period without the occurrence of a revocation by the Executive (or such later date as may be required under Section
19 of this Agreement). Nevertheless (and regardless of whether the General Release has been executed by the Executive), upon any termination
of the Executive&#8217;s employment, the Executive shall be entitled to receive any Accrued Amounts, payable after the date of termination
in accordance with the Company&#8217;s applicable plan, program, policy or payroll procedures. Notwithstanding anything to the contrary
in this Agreement, if any severance pay or benefits are deferred compensation under Section 409A (as defined below), and the period during
which the Executive may sign the General Release begins in one calendar year and the first payroll date following the period during which
the Executive may sign the General Release occurs in the following calendar year, then the severance pay or benefit shall not be paid
or the first payment shall not occur until the later calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>CONSEQUENCES OF A CHANGE IN CONTROL</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon the closing of a Change in Control (as defined below), all unvested stock options and other equity awards shall immediately
vest and the time period that the Executive shall have to exercise all vested stock options and other awards that the Executive may have
under the Plan (including the Initial Grant) or any successor equity compensation plan as may be in place from time to time shall be
equal to the shorter of: (i) eighteen (18) months days after termination, or (ii) the remaining term of the award(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If within one year after the occurrence of a Change in Control, the Executive terminates his employment with the Company for Good
Reason or the Company terminates the Executive's employment for any reason other than death, Disability or Cause, the Company (or the
then former Company subsidiary employing the Executive), or the consolidated, surviving or transferee person in the event of a Change
in Control pursuant to a consolidation, merger or sale of assets, the Executive shall be entitled to receive from the Company (i) the
portion of the Base Salary for periods prior to the effective date of termination accrued but unpaid (if any); (ii) all unreimbursed
expenses (if any), subject to Section 7(b); (iii) an aggregate amount (the &#8220;Change in Control Severance Amount&#8221;) equal to
two times the sum of the Base Salary plus an amount equal to the bonus that would be payable if the &#8220;target&#8221; level performance
were achieved under the Company's annual bonus plan (if any) in respect of the fiscal year during which the termination occurs (or the
prior fiscal year if bonus levels have not yet been established for the year of termination). The Change in Control Severance Amount
shall be paid in a lump sum, if the Change in Control event constitutes a &#8220;change in the ownership&#8221; or a &#8220;change in
the effective control&#8221; of the Company or a &#8220;change in the ownership of a substantial portion of a corporation's assets&#8221;
(each within the meaning of Section 409A), or in 48 substantially equal payments, if the Change in Control event does not so comply with
Section 409A. The lump sum amount shall be paid, or the installment payments shall commence, as applicable, on the first scheduled payroll
date (in accordance with the Company's payroll schedule in effect for the Executive immediately prior to such termination) that occurs
on or following the date that is 30 days after the Executive's termination of employment; <I>provided, however</I>, that the payment
of such <FONT STYLE="font-size: 10pt">Change in Control Severance Amount and</FONT> is subject to the Executive's compliance with the
requirement to deliver the General Release contemplated pursuant to Section 12(b). Any such installment payment shall be treated as a
separate payment as defined under Treasury Regulation &sect;1.409A-2 (b)(2). If the Executive is a &#8220;specified employee&#8221; (as
determined under the Company's policy for identifying specified employees) on the date of his &#8220;separation from service&#8221; (within
the meaning of Section 409A) and if any portion of the severance amount described in clause (iii) would be considered &#8220;deferred
compensation&#8221; under Section 409A, such severance amount shall not be paid or commence to be paid on any date prior to the first
business day after the date that is six months following the Executive's separation from service (unless any such payment(s) shall satisfy
the short-term deferral rule, as defined in Treasury Regulation &sect;1.409A-1(b)(4), or shall be treated as separation pay under Treasury
Regulation &sect;1.409A-1(b)(9)(iii) or &sect;1.409A-1(b)(9)(v)). If paid in installments, the first payment that can be made shall include
the cumulative amount of any amounts that could not be paid during such six-month period. In addition, interest will accrue at the 10-year
T-bill rate (as in effect as of the first business day of the calendar year in which the separation from service occurs) on such lump
sum amount or installment payments, as applicable, not paid to the Executive prior to the first business day after the sixth month anniversary
of his separation from service that otherwise would have been paid during such six-month period had this delay provision not applied
to the Executive and shall be paid at the same time at which the lump sum payment or the first installment payment, as applicable, is
made after such six-month period. Notwithstanding the foregoing, a payment delayed pursuant to the preceding three sentences shall commence
earlier in the event of the Executive's death prior to the end of the six-month period. Upon the termination of employment with the Company
for Good Reason by the Executive or upon the involuntary termination of employment with the Company of the Executive for any reason other
than death, Disability or Cause, in either case within two years after the occurrence of a Change in Control, the Company (or the then
former Company subsidiary employing the Executive), or the consolidated, surviving or transferee person in the event of a Change in Control
pursuant to a consolidation, merger or sale of assets, shall also provide, for the period of two consecutive years commencing on the
date of such termination of employment, medical, dental, life and disability insurance coverage for the Executive and the members of
his family which is not less favorable to the Executive than the group medical, dental, life and disability insurance coverage carried
by the Company for the Executive and the members of his family at the time of termination; <FONT STYLE="font-size: 10pt"><I>provided,
however</I>, that such payments are subject to the Executive's compliance with the requirement to deliver the General Release contemplated
pursuant to Section 12(b)</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, &#8220;Change in Control&#8221; means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)
any person or entity becoming the beneficial owner, directly or indirectly, of securities of the Company representing fifty percent (50%)
of the total voting power of all its then outstanding voting securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)
a merger or consolidation of the Company in which its voting securities immediately prior to the merger or consolidation do not represent,
or are not converted into securities that represent, a majority of the voting power of all voting securities of the surviving entity
immediately after the merger or consolidation; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)
a sale of substantially all of the assets of the Company or a liquidation or dissolution of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>ASSIGNMENT</U></B>. This Agreement shall be binding upon and inure to the benefit of the Executive and the Executive&#8217;s
heirs, executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature
of the Executive&#8217;s duties under this Agreement, neither this Agreement nor any rights or obligations under this Agreement shall
be assignable by the Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns
and legal representatives. Any such successor or assign of the Company will be deemed substituted for the Company under the terms of
this Agreement for all purposes. For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity
which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or
business of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>NOTICE</U></B>. For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall
be in writing and shall be deemed to have been duly given (a) on the date of delivery if delivered by hand, (b) on the date of transmission,
if delivered by confirmed facsimile, (c) on the first business day following the date of deposit if delivered by guaranteed overnight
delivery service, or (d) on the fourth business day following the date delivered or mailed by United States registered or certified mail,
return receipt requested, postage prepaid, addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Synthetic
Biologics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">9605
Medical Center Drive, Suite 270</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rockville,
Maryland 20850</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention:
Board of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Facsimile:
(734) 332-7878</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">and
a copy (which shall not constitute notice) shall also be sent to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gracin
 &amp; Marlow, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">405
Lexington Avenue, 26<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
York, New York 10174</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention:
Leslie Marlow, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Facsimile:
(212) 208-4657</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
to the Executive:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
the most recent address of the Executive set forth in the personnel records of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">or
to such other address as either party may have furnished to the other in writing in accordance herewith, except that notices of change
of address shall be effective only upon receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>SECTION HEADINGS; INCONSISTENCY</U></B>. The section headings used in this Agreement are included solely for convenience
and shall not affect, or be used in connection with, the interpretation of this Agreement. If there is any inconsistency between this
Agreement and any other agreement (including but not limited to any option, stock, long-term incentive or other equity award agreement),
plan, program, policy or practice (collectively, &#8220;<B><I>Other Provision</I></B>&#8221;) of the Company the terms of this Agreement
shall control over such Other Provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <B><U>SEVERABILITY</U></B>. The provisions of this Agreement shall be deemed severable and the invalidity of unenforceability
of any provision shall not affect the validity or enforceability of the other provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>COUNTERPARTS</U></B>. This Agreement may be executed in counterparts, each of which shall be deemed to be an original but
all of which together will constitute one and the same instruments. One or more counterparts of this Agreement may be delivered by facsimile,
with the intention that delivery by such means shall have the same effect as delivery of an original counterpart thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>SECTION 409A</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary herein, the following provisions apply to the extent severance benefits provided herein
are subject to Section 409A of the Internal Revenue Code (the &#8220;<B><I>Code</I></B>&#8221;) and the regulations and other guidance
thereunder and any state law of similar effect (collectively &#8220;<B><I>Section 409A</I></B>&#8221;). Severance benefits shall not
commence until the Executive has a &#8220;separation from service&#8221; (as defined under Treasury Regulation Section 1.409A-1(h), without
regard to any alternative definition thereunder, a &#8220;separation from service&#8221;). Each installment of severance benefits is
a separate &#8220;payment&#8221; for purposes of Treas. Reg. Section 1.409A-2(b)(2)(i), and the severance benefits are intended to satisfy
the exemptions from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4) and 1.409A-1(b)(9). However,
if such exemptions are not available and the Executive is, upon separation from service, a &#8220;specified employee&#8221; for purposes
of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A, the timing of the
severance benefits payments shall be delayed until the earlier of (i) six (6) months and one day after the Executive&#8217;s separation
from service, or (ii) the Executive&#8217;s death. The parties acknowledge that the exemptions from application of Section 409A to severance
benefits are fact specific, and any later amendment of this Agreement to alter the timing, amount or conditions that will trigger payment
of severance benefits may preclude the ability of severance benefits provided under this Agreement to qualify for an exemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>It is intended that this Agreement shall comply with the requirements of Section 409A, and any ambiguity contained herein shall
be interpreted in such manner so as to avoid adverse personal tax consequences under Section 409A. Notwithstanding the foregoing, the
Company shall in no event be obligated to indemnify the Executive for any taxes or interest that may be assessed by the Internal Revenue
Service pursuant to Section 409A of the Code to payments made pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>SECTION 4999 EXCISE TAX</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If any payments, rights or benefits (whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement
of the Executive with the Company or any person affiliated with the Company) (the &#8220;<B><I>Payments</I></B>&#8221;) received or to
be received by the Executive will be subject to the tax (the &#8220;<B><I>Excise Tax</I></B>&#8221;) imposed by Section 4999 of the Code
(or any similar tax that may hereafter be imposed), then, except as set forth in Section 20(b) below, the Company shall pay to the Executive
an amount in addition to the Payments (the &#8220;<B><I>Gross-Up Payment</I></B>&#8221;) as calculated below. The Gross Up Payment shall
be in an amount such that, after deduction of any Excise Tax on the Payments and any federal, state and local income and employment tax
and Excise Tax on the Gross Up Payment, but before deduction for any federal, state or local income and employment tax on the Payments,
the net amount retained by the Executive shall be equal to the Payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The process for calculating the Excise Tax, determining the amount of any Gross-Up Payment and other procedures relating to this
Section 20, including the time period for making the Gross-Up Payment, are set forth in <B><I>Appendix A</I></B> attached hereto. For
purposes of making the determinations and calculations required herein, the Accounting Firm (as defined in <B><I>Appendix A</I></B>)
may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code, <I>provided that
</I>the Accounting Firm shall make such determinations and calculations on the basis of &#8220;substantial authority&#8221; (within the
meaning of Section 6662 of the Code) and the Company shall use reasonable efforts to cause the Accounting Firm to provide opinions to
that effect to both the Company and Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>REPRESENTATIONS</U></B>. The Executive represents and warrants to the Company that the Executive has the legal right to
enter into this Agreement and to perform all of the obligations on the Executive&#8217;s part to be performed hereunder in accordance
with its terms and that the Executive is not a party to any agreement or understanding, written or oral, which could prevent the Executive
from entering into this Agreement or performing all of the Executive&#8217;s obligations hereunder. The Executive further represents
and warrants that he has been advised to consult with an attorney and that he has been represented by the attorney of his choosing during
the negotiation of this Agreement, that he has consulted with his attorney before executing this Agreement, that he has carefully read
and fully understand all of the provisions of this Agreement and that he is voluntarily entering into this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">22.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>WITHHOLDING</U></B>. The Company may withhold from any and all amounts payable under this Agreement such federal, state
and local taxes as may be required to be withheld pursuant to any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">23.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>SURVIVAL</U></B>. The respective obligations of, and benefits afforded to, the Company and the Executive which by their
express terms or clear intent survive termination of the Executive&#8217;s employment with the Company, including, without limitation,
the provisions of Section 8 and Sections 10 through 29, inclusive of this Agreement, will survive termination of the Executive&#8217;s
employment with the Company, and will remain in full force and effect according to their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">24.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>AGREEMENT OF THE PARTIES</U></B>. The language used in this Agreement will be deemed to be the language chosen by the parties
hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto. No agreements or
representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which
are not expressly set forth in this Agreement. Neither the Executive nor the Company shall be entitled to any presumption in connection
with any determination made hereunder in connection with any arbitration, judicial or administrative proceeding relating to or arising
under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">25.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <B><U>INTEGRATION</U></B>. This Agreement, together with the Confidentiality Agreement and the Grant Agreements, contains the
complete, final and exclusive agreement of the parties relating to the terms and conditions of the Executive&#8217;s employment and the
termination of the Executive&#8217;s employment, and supersedes all prior and contemporaneous oral and written employment agreements
or arrangements between the parties, including but not limited to the Prior Employment Agreement. The Executive acknowledges and agrees
that the Company has fully satisfied, and has no further obligations to the Executive arising under, or relating to, the Prior Employment
Agreement or any other employment or consulting arrangement or understanding or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">26.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>AMENDMENT.</U></B> This Agreement cannot be amended or modified except by a written agreement signed by the Executive and
a duly authorized officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">27.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>WAIVER</U>. </B>No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with
the written consent of the party against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall
not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">28.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>CHOICE OF LAW</U>. </B>This Agreement shall be construed and interpreted in accordance with the internal laws of the State
of Nevada without regard to its conflict of laws principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">29.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>DISPUTE RESOLUTION</U></B>. To ensure the rapid and economical resolution of disputes that may arise in connection with
the Executive&#8217;s employment with the Company, the Executive and the Company both agree that any and all disputes, claims, or causes
of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance,
or interpretation of this Agreement, the Executive&#8217;s employment with the Company, or the termination of the Executive&#8217;s employment
from the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &sect;1-16, and to the fullest extent permitted
by law, by final, binding and confidential arbitration conducted in Delaware by JAMS, Inc. (&#8220;<B><I>JAMS</I></B>&#8221;) or its
successors. <B>Both the Executive and the Company acknowledge that by agreeing to this arbitration procedure, each waives the right to
resolve any such dispute through a trial by jury or judge or administrative proceeding. </B> Any such arbitration proceeding will be
governed by JAMS&#8217; then applicable rules and procedures for employment disputes, which can be found at <FONT STYLE="font-variant: small-caps"><B>http://www.jamsadr.com/rules-clauses/</B></FONT>,
and which will be provided to the Executive upon request. In any such proceeding, the arbitrator shall: (i) have the authority to compel
adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue
a written arbitration decision including the arbitrator&#8217;s essential findings and conclusions and a statement of the award. The
Executive and the Company each shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law;
<I>provided, however,</I> that in no event shall the arbitrator be empowered to hear or determine any class or collective claim of any
type. Nothing in this Agreement is intended to prevent either the Company or the Executive from obtaining injunctive relief in court
to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. The Company shall pay all filing
fees in excess of those which would be required if the dispute were decided in a court of law, and shall pay the arbitrator&#8217;s fees
and any other fees or costs unique to arbitration. Notwithstanding the foregoing, nothing in this Section 29 shall prevent the Company
from seeking and obtaining a judicial junction in a court of competent jurisdiction to enforce a violation of Section 8 (and the Agreement
referenced in Section 8) or 9 of this Agreement. Executive hereby agrees to waive a jury and filing of a bond for any such action by
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement, effective as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC
    BIOLOGICS, INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    T. J. Swope</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    T. J. Swope</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Secretary</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    January 3, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    A. Shallcross</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    January 3,2022</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>APPENDIX
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TAX
GROSS-UP PAYMENT RULES AND PROCEDURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to Paragraph 3 below, all determinations required to be made under Section 20 of this Agreement, including whether a Gross-Up
Payment is required and the amount of such Gross-Up Payment, shall be made by an accounting firm (the &#8220;<B><I>Accounting Firm</I></B>&#8221;)
selected in accordance with Paragraph 2 below. The Company shall use reasonable efforts to cause the Accounting Firm to provide detailed
supporting calculations both to the Company and Executive within 15 business days before the event that results in the potential for
an excise tax liability for the Executive, which could include but is not limited to a Change in Control and the subsequent vesting of
any cash payments or awards, or the Executive&#8217;s termination of employment, or such earlier time as is required by the Company.
The initial Gross-Up Payment, if any, as determined pursuant to this Paragraph 1, shall be paid on the Executive&#8217;s behalf to the
applicable taxing authorities by no later than the date the Executive is required to remit the taxes to such taxing authority. If the
Accounting Firm determines that no Excise Tax is payable to the Executive, the Company shall use reasonable efforts to cause the Accounting
Firm to furnish the Executive with a written report indicating that he has substantial authority not to report any Excise Tax on his
federal income tax return. Any determination by the Accounting Firm shall be binding upon the Company and Executive. As a result of the
uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accounting Firm hereunder,
it is possible that Gross-Up Payments which will not have been made by the Company should have been made (&#8220;<B><I>Underpayment</I></B>&#8221;),
consistent with the calculations required to be made hereunder. In the event that the Company exhausts its remedies pursuant to Paragraph
3 below and the Executive thereafter is required to make a payment or additional payment of any Excise Tax, the Accounting Firm shall
determine the amount of the Underpayment that has occurred and any such Underpayment, increased by all applicable interest and penalties
associated with the Underpayment, shall be promptly paid by the Company to or for the benefit of the Executive. For purposes of determining
the amount of the Gross-Up Payment, the Executive shall be deemed to pay federal income tax at the highest marginal rate of federal income
taxation in the calendar year in which the Gross-Up Payment is to be made and state and local income taxes on earned income at the highest
marginal rate of taxation in the state and locality of the Executive&#8217;s residence on the Effective Date of Termination, net of the
maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Accounting Firm shall be a public accounting firm proposed by the Company and agreed upon by the Executive. If the Executive
and the Company cannot agree on the firm to serve as the Accounting Firm within ten (10) days after the date on which the Company proposed
to the Executive a public accounting firm to serve in such capacity, then the Executive and the Company shall each select one accounting
firm and those two firms shall jointly select the accounting firm to serve as the Accounting Firm within ten (10) days after being requested
by the Company and the Executive to make such selection. The Company shall pay the fees of the Accounting Firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> The Executive shall notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would require
the payment by the Company of the Gross-Up Payment. Such notification shall be given as soon as practicable but no later than fifteen
(15) business days after the Executive knows of such claim and shall apprise the Company of the nature of such claim and the date on
which such claim is requested to be paid. The Executive shall not pay such claim prior to the expiration of the period ending on the
date that any payment of taxes with respect to such claim is due or the thirty (30) day period following the date on which the Executive
gives such notice to the Company, whichever period is shorter. If the Company notifies the Executive in writing prior to the expiration
of such period that it desires to contest such claim, the Executive shall (i) give the Company any information reasonably requested by
the Company relating to such claim, (ii) take such action in connection with contesting such claim as the Company shall reasonably request
in writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney
reasonably selected by the Company, (iii) cooperate with the Company in good faith in order effectively to contest such claim, and (iv)
permit the Company to participate in any proceedings relating to such claim; <I>provided, however</I>, that the Company shall bear and
pay directly all costs and expenses (including attorneys&#8217; fees and any additional interest and penalties) incurred in connection
with such contest and shall indemnify and hold the Executive harmless, on an after-tax basis, for any Excise Tax or income tax, including
interest and penalties with respect thereto, imposed as a result of such representation and payment of costs and expenses. Without limitation
of the foregoing provisions of this Paragraph 3, the Company shall control all proceedings taken in connection with such contest and,
at its sole option, may pursue or forego any and all administrative appeals, proceedings, hearings and conferences with the taxing authority
in respect to such claim and may, at its sole option, either direct the Executive to pay the tax claimed and sue for a refund or contest
the claim in any permissible manner, and the Executive agrees to prosecute such contest to a determination before any administrative
tribunal, in a court of initial jurisdiction and in one or more appellate courts, as the Company shall determine; <I>provided, however</I>,
that if the Company directs the Executive to pay such claim and sue for a refund, the Company shall advance the amount of such payment
to Executive, on an interest-free basis and shall indemnify and hold the Executive harmless, on an after-tax basis, from any Excise Tax
and income tax, including interest or penalties with respect thereto, imposed with respect to such advance or with respect to any imputed
income with respect to such advance; and further <I>provided that</I> any extension of the statute of limitations relating to payment
of taxes for the taxable year of the Executive with respect to which such contested amount is claimed to be due is limited solely to
such contested amount. Furthermore, the Company&#8217;s control of the contest shall be limited to issues with respect to which a Gross-Up
Payment would be payable hereunder and the Executive shall be entitled to settle or contest, as the case may be, any other issue raised
by the Internal Revenue Service or any other authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If, after the receipt by the Executive of an amount advanced by the Company pursuant to Paragraph 3 above, the Executive becomes
entitled to receive any refund with respect to such claim, the Executive shall (subject to the Company&#8217;s complying with the requirements
of Paragraph 3), promptly pay to the Company the amount of such refund (together with any interest paid or credited thereon after taxes
applicable thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>syn-20220103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>syn-20220103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://syntheticbiologics.com/role/Cover" xlink:href="syn-20220103.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://syntheticbiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>syn-20220103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaqBqbOdzZR+uYkxtmB8bXlarysu8K7Sfi5n0EhGgTEB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:syn="http://syntheticbiologics.com/20220103" elementFormDefault="qualified" targetNamespace="http://syntheticbiologics.com/20220103">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://syntheticbiologics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="syn-20220103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="syn-20220103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140256066072184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  03,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SYNTHETIC BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>tm221380d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syn-20220103.xsd" xlink:type="simple"/>
    <context id="From2022-01-03to2022-01-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-03to2022-01-03">0000894158</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-03to2022-01-03">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-01-03to2022-01-03">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-03to2022-01-03">2022-01-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-01-03to2022-01-03">SYNTHETIC BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-03to2022-01-03">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-01-03to2022-01-03">001-12584</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-03to2022-01-03">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-03to2022-01-03">9605 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-03to2022-01-03">Suite 270</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-03to2022-01-03">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-03to2022-01-03">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-03to2022-01-03">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-03to2022-01-03">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-03to2022-01-03">417-4364</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-01-03to2022-01-03">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-01-03to2022-01-03">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-01-03to2022-01-03">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-01-03to2022-01-03">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-01-03to2022-01-03">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-03to2022-01-03">SYN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-03to2022-01-03">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-03to2022-01-03">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "NBB14!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M *Z*)%2@$XJI[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( *Z*)%297)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ KHHD5'+2
M;P-7!   W1   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( *Z*)%2?H!OPL0(  .(,   -
M  "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @ KHHD5)>*NQS
M$P(   L              ( !=@\  %]R96QS+RYR96QS4$L! A0#%     @
MKHHD5*K$(A8S 0  (@(   \              ( !7Q   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( *Z*)%0D'INBK0   /@!   :              "
M ;\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *Z*
M)%1ED'F2&0$  ,\#   3              "  :02  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  .X3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm221380d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://syntheticbiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm221380d1_8k.htm">tm221380d1_8k.htm</File>
    <File>syn-20220103.xsd</File>
    <File>syn-20220103_lab.xml</File>
    <File>syn-20220103_pre.xml</File>
    <File>tm221380d1_ex10-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm221380d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm221380d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20220103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20220103_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "syn-20220103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "syn",
   "nsuri": "http://syntheticbiologics.com/20220103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm221380d1_8k.htm",
      "contextRef": "From2022-01-03to2022-01-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://syntheticbiologics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm221380d1_8k.htm",
      "contextRef": "From2022-01-03to2022-01-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-22-000998-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-000998-xbrl.zip
M4$L#!!0    ( *Z*)%30!=R7/@,  ! ,   0    <WEN+3(P,C(P,3 S+GAS
M9+56VW+:,!!];F?Z#ZI?,_(%2I,02";W84J:#B1IFI>.L 5H(B0CR0'Z]95D
M&P@8 J3UD[PZY^RNM+MV[60\H. %"TDXJSN!ZSL LY!'A/7JSGT;GK;/&PT'
MG!Q_^@CT4_L,(;@BF$95<,%#V&!=?@2^HP&N@FO,L$"*BR/P@&AB+/R*4"S
M.1_$%"NL-U)/55!Q@P !"#?0?< LXN*^U9CJ]I6*9=7S1J.1R_@+&G'Q+-V0
M#S83;"ND$CE5\\=^]FQ&OR$RG)+WT&EEM#]ND<<>9@=)$Y6?PI]H>#;LW$9_
MGEI[R:_GL1J<'70>*1(3F1Q\VV]W287YE_WKWMWE6>JR)L,^'B"@+X/)NF/R
MR](;E5TN>E[)]P/O\:;9MC@G!5;'E+#G(GAP>'CHV=T<NH0<=P3-I<N>V>X@
MB:?*>I>LP1,F%6+A*WRDIH1Y<,5+-U]!22'T:PHE.33""SB)0[?'7SR]H?&E
M8/@EAR82]A"*I_ NDATKFVU8./0#6 YRBA1J&:Z-Q5"H)C&6A81TJX@V85."
M7JL^5B3L$$YYCX2V8 VIY =^6;<=Q0/,U!47@PO<10G5T0T31$F7X,@!"HD>
M5J8"98Q"O+%N7M"(,:[K7C=?9C&V.":ZL+7A0\U40%5PBN]T,L L=,>]Y<7
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MJW9<*EF L)C>^E"1>F^@S+:<-YS#O0\L=78SM\=L=5\7T 4!2X^YUMU>)6_
MXK$WNJ1YDN_E\W@WV\V*<$L!VQ)7?$#F-!=F>A \ *9,#I0,21U20F^UK^\J
MT%P^" D6R92YI<!NLDE"4Q,0#59C !$';?%<JC<J9J*5XCB=TYCL?B)[L&PM
MG5LN )M-, Q10&38G0%HE&)4J)&0>X/CCB<;S/>+).KI-MI"MWA 1IM\F*J
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M:!Z J:4/$2G(9"]8*M W7PL2;45_N9\>KY9)GMI./-L29_T38*[JG8ST(/@
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MRI=$3$O:N%ZZ0'V', :DIPO%+2)?4:%\-)XJ 5T @N_ ]-';Q *:)!=;9&?
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MDAD>6ADP%&_EI M;FQLRRPG!0E_'4+'+8$I."P*:]T4SO1;S204&CE#.D;Q
M2SAT):'ES$(.P'DX"XWGG2'O@>FV\LW;6&)ISXR+7IBU+%">D(:BIY=^1<E
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M\=]Y<9$ET[-DRD\OH[).8;KX@[K ==6@UJ;Y&7*W21)DR1E1^J1H\JD,@[8
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MGB6*.9I;X3I,2(] 38P=KN(E]92*[6"8:V],RTU&&TC^FY4G2),$RQVG'EW
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M.)?>0)V]S(%]EVUT*ZE9H.[3E2,=X=V#T^&(Q:3. Y *>Y9UU+!==V\OT\I
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M%DL\HU#M;'L<OG8&-AWV3.U_K'],#/ B3\B5KPZ$0E'^3Z7,0E-_S*_1S[1
M*:][&W,$JZ[%SB]"3E#"OVFK\+CIVLO+^KT-2NS72.<)-4X4/<[V.FVJ'(I'
MS]P*&J%<XY^^9ANG1<)%_Y64+E]*[,Q^&Y^H.AIU1YS3TXPTA6.!SQTON49(
M9C<P%U]HSU_HMFLW]97BTU+UH%>[%/]9:1^8&L$KE7(YZ^HF!S8M\ZWGV]/O
ML9SKP-7DBI@J>+CC:&^>Y%N)IMQ=BZJ:?8N**YMIG-]7ZQW7WS\K)HIS7Y41
M],^J5=-.+$1\XJH&0Z)NG1Y$ZDD)0U R84?>4K"[!T* DY]H:1U$9,BM!G4!
M!T(B0N36943]E]7O+,N&^>L8U8L&>/PIU0'3"_]1P9M?[FXC=6_M!?#VC;W-
M-H0!=?!3UQTY+[=L5J$]Q2,V$ C(2@GLXNOBST9"Y!:5,U)'VH.:>CTEAU$9
M4W/@U>KH996 HA*;B3#G8):VBG60&96JN):C*!C7K=QQU6Z"N'.<<<(G]Q)5
MDA 9<3JEK 69I'*=4ZL2;3VI.;9=Z%+BTWIYRU_LQ)*X[H<_YF ([9>CTQ!'
MP9HQDRSA!R[4U47@H\Y"1_LBK-C^8$-: >A0F! CXCGR*AB(6%)@R0S<(LN-
M]PKS4)HL"0,7%_A:RMU%PGW$PJ#K?ECS15^\>Q]0=[]BV.>;?- P=.>7YYM\
M893LMNZLJ+&N5Y\V&NO;5;66. _(*F<-/HB;1<-=?Q0-J+0<"2WR($1Z-EV(
M[L-DE'[<LOO&>Y@ZV-"@1!\%91:K<GIFL;L[6ZC0]'OCK0E^2WQEPP%8,$%[
M7IU#6@I8VHG3J%Q?N6#=!,02AFX^1R%!UF+,50M;DO9MR=H2I;@KW?'5]L4(
M5MP+V,%:ROU0'46V7E$L37C1JD6PK*P54 )S"-(C27^\]J3@M]- VOMDD=T0
M&%=%J[1:#-O83%,OYBSG644+\4&AZJX/02LRN@S0CD)U;'-KE[$+-F.QTZ:M
MH+MKJFTC_7Y:KB<:.;G1('B@^8GI5\C[?(4*3"T%XWU5PNX_)56WJU91';RW
M!.U/O+K]ARWK&(O+;@;2"K;#]QK::E5?T*M?TNZ>V^5+4$U$KW FX,U.R>\0
MJUP(W$,P&?'R5I_N3O$\$Q06I2WYIIX):YI@_'V>9T( 2+*J4$GH3H6#1GHI
MN*69G MOHU"J (J0_JBTFZL;C82J>35V7@<J@?\24B3>^:DYT Z0@+;*K[S2
M"^SZ3GWP^CWD-NSJ$P8A_91)G,^B\Z*T4V<L7YGJ=L*@$I\[R3@JR[2C8=!-
M)A]8<Q>&1[S.AR2_VDZP+0_8CI;I8:LSG!GQ:89"\)EV@DNFCJ$@1LLZ\O^I
MD?_GZ\C_+4?^GZ\C_]_]A:'_W4WS&T6MOS3O&;;\YG&<&W;!;8EP94JCA5_=
M>@'4W>W7-PSZ?6%V G59( <*ZUT8,,8(S247)BAU3I?#9>P>5AGF&7<WRM6_
M0E*$0(Z6W+#6<SJ7B=1>X+C<ZA7>&U,&\>.=_]K4J9]U <I'<%[0#Y<@R\DY
M3V9VS2U@@Z*IM4$B/S0OOI=G<9^IB,C(TKD=9=PG ^U)P,-LG5VW1YM5QN[A
MIP6INIJZ0LK'1!4//X;?8A8S>:+0-6Y>1'JA>8JZ%O_%G9QEQET4V)ZPLCJU
M2<-7J-^S5V(,L!7+P+#.?3S\>TVV3+?*0G0C4%Q1PPDI9#IVQM"R%,P"1><E
MFDEPI$T'V:_1(NXVA_'1W>4P[H]&P[='OPV.QJ8 ?MR%AC4!49JRS)+2!^1*
MV-Y9A>@EQ;SE%E)F<P<(XSQ)$:2!ZRP(KX&%.16%FF+'<^HP7V%Z//XQ!>&>
M4E?8HN2,M"PY:S^R';Q.8@J7R)2:' @^4=6-_!JPT!LLQE]=64\-[CMKA\(@
M%\>55U.4*T<8@X3!OP2/GE+H.LN0:),)]9#722X/WVMW2T>C6R+C[^K*9-R9
M7>;ZN17;JF.$)E4/%TQ/^N]0X"'259[8%*4,F 0&]=-V*S1T'CKK)0]CEFF-
M?3MXHUJ9R4=:8]=S<S3UP"B,(3J;%Z&=#$ G10>JW?)*'K+4MZ 90UU"!*<$
M+X_G5(UE)*3VPJ_2.(,H)K=,Q>RZO)Z'EU8<[5MPZ/O!C6_FB-G=67MB;MD3
ML[NS=L7<SRMSVPK,X[M38(Z.Q\.#@5%>WJAP",N#+I].3FW7*PTTP2P?XR.@
M(<0BI37(STPAY:R0UV@2HC5%)9!3&TF")!Z(8!-_G3; V,] BN;!1M1*,M%5
M\^G,PJ&88#)]/@TQ0\9_@J)/"]#;,6X$1IOW'!AI*.-P$5%<I7!V((PVXDTW
MV\L)07=W+)XF5'K?FAA" 6&_*_@7AE-RU'<P#4?6(5%ISIN?FM<6#;9YONZ]
MYDWP^")*,W[GAYQ AT<UI3:7R1FH@NI7,5C+G,J#OP\Q0PK4NYS3=9<U!4*H
MJB&D<G*\_:#;</)<-)V"+*XX:T,0^]?(1I_EDMQZM/WX"\21X.4YT!'?U,7Z
MQ>OY+H[DX1<M8729PW$ X^SW7J=%5IRE,7PYS.-;5SWO=%G/G^P\[O=^X]AQ
M<$#*5G"(N,_PDP:;*.\]W;G7*SPMXK_/P0I+@!W^%I67&4JIO9UGC^_WLO9K
M; <)<N\%$&0+^/%><XLW2EC#TC:>/GRT&3Q\N+?U]-G39_=Z6=\%$_RR)<#5
M0:=K7"P]Y##QUHMO0S3,33M?9\*Y8Z /KD79-U["VS**,4,[^$>T6+X,@"F"
MKA<&[]^?W.ME/4))]C[Y"$IT#9KV/E@9#4BQO2>O1A].?JWGKQ[@?X,W67'[
MT9H[72A\T>_]691_A_0;_ MFO/OTT;U>E2W0WB=5EB::,@?5O[^UEG6+$FT/
M&QJ! K+UZ,GCI_=Z63\ +[0L+1UFN%L!]7WN_Y.GN+$W,]?WON@$QH74"A55
M38X*+*!B7T0[EE8E% 2AGEPJZ[?"/EP8IL'"O&\3&+CE+?F&GL\O\KQ@@$:5
M, I(AAQD5*D<]V54UI<:(B.8-67.];QR"_DYRZGHUEPBYBOF]6+0%#%M.1-$
M>33A[&,I@\>4#WFYJ6#7%;;8-YN#A>(:^S9T\AWZN>[$/_[D[OSCH\$!-9!^
M-]@_'!Z]';T,AD<(7#0<C0='!W_:47]D+YSC/4\B#"=705,ETP[O-R8H2=78
M% -=F"4TXZP@T#I3+HAQNK(C-FN"3=\(C$Z/Z_40#*4>I4[*99D(SG'+@Z^*
M1$LN#J6T+"J!K+ T!_/_ZHLDX4GW>]:L!2E3KJ:! #6P-!VM[>B))5=F$!9.
M2%#*7#L(3Z+2Q@4U;7@>\Y+-D'N =<,K@D%24Q%C7&097U',2'30HH]I]!-5
MD-7NO.L&WNTXNK=_JNI?RNS)=<],RWO'&K7JLV9^D^CS[CKZ?-O1Y]UU]/F'
MOUJ?+7&??MUN,H$2MK\/3O=?#]\/QYYD=9MD=/:;M+*DJ R?('XE=R[-SV%_
MII+?V^1)#H0:)U+6QMI>;I?K^H*7<X+U&)@K;X^@I(??54&:>*P%P=U2Z[.[
MZ7WTX6@\.#W9/QV/5B9_"LZ>1L(FG:TA!0T,&<S=1+0< M3V^FBH[ =,:<3,
MNA3V$%&5L#FLY+9)/7AQQHETE"MH>=$14$U= *HCQ[KPLJ$RR.W@.">E:P$,
MVYE2Q_V213BI"R8C@IOF:LTSE^8:46T2,B:2\,@YA#9FHIJ:P2;0#W'C$[UP
M:XZLO*ZOU5U?J^=W;W8A7L<:!/:G X'U<2=6@>.3?$US 6O1.5"6 $;,"]U'
M!;:'](5VJT6=KL8# HMUR\0=O'P1]D/D1SD5?U.L"&S':=+1IP@_;IF;BC&7
M&L#&!H<]P\(2\@(0J^/4;MVI E.WJ*L\%JX@$XY*Q4 ="]CK5VXMP9_.M@6M
MI?=$ZT"$@L2010;(WNZS84-,70/O="-L*UTKK_!ZYIMA5VMTRL+/Z!08]A%'
M3DUW)WI#>-/)P2X,(@^ZBXH:VXTY*ZH=4KA=,KI #*BESKS26%KH-BYSVU_@
M'J-W;:16XX6.U[+;"$AXRJJ!@\@$*L9"0(:Y*Q"#O2@7D$/ FMI7'D&E'J@"
M%ZB)YN?B*&T'[QAS@5,H2=);LU'5>-%Y!)1J:^4V2)ET!%EQ0N%-,,SL#2>5
MWD7HPMK14'G;7(:0)UCK$''#I>B\0/R=*6(&):;2I8X^,BH(V\55)PJ8(%@(
M9AF!A'0Q&Q=4D%4K@L\QUTO!X< PB(F*V%X;3TSS8N04>>*A'K6K;\QV]GON
M?MI0S"OZ88KE!0H75O!$,3:1RY+IF< D?2K1406F[ 5F_EI$#<IDK7#D8M.2
MAWME@'J83]5E]#13/*Y,+9\W/K3PIN"\IM+QBK%/44.N0:.D3FXV&F'[D!8$
MWY20DY:K2(RI=Y4 Z2Q/@GDBJ"4(:4'Y,3NW1KK^69"N":3/\&^^0QV.# O$
MU(>?J?Q;92Y+M)BD9P+XGM<125A69IQD>PD-L"G*1EF4Y^C +M#Z^B+^=RU>
M&#%$C2 EX'D@' 3M"28HA7XLW_#4%SE>FFZ@+)A24G%1F"#BT::*N8I57Y2/
M+F6 OKJ& +&,^M8%TV,K>J37P7>:;Q-PF@MUY@18[M_5^*I7^K9LJ;V=;V"
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M0S1;8!JE.91.]UP5[#W;>4O3]]6OT&[K0=H%$L?PUZZ%L%2%[4E8%[EN=T2
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M$!T(H8X)::1C?E0JK^43F]GJ@!<>22Q_FY7G>A-%7N8)^OFG60"L:50-YIZ
M=<S Z]RG16:!O>] .\B3HJE832#M6CQY]A3TYDC'%IT04UGX WKM=O2G V.
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M\8TJ6K[. 8_W7[\?! >#]^]/]@\QP_B_?]GYA?X].MD_4/]6%XDY$FI?8$G
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M\\HMZIHD$I!%R51IUMV?2SIBYB@7N:$(M\]RYHJ=1+S)^I/SAI>VM]W"#:@
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M+GAS9%!+ 0(4 Q0    ( *Z*)%3YKCU/_PH  &R'   4              "
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2      4 !0!$ 0  -W\

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
